MYC and breast cancer: The p53-proficient MCF-7 breast cancer cell line, which is deficient of p14/ARF and p16, represents a luminal, estrogen-receptor-positive breast cancer subtype in which endogenous c-MYC expression is amenable to regulation by both estrogens and anti-estrogens [12,20,21].